Optimizing Oncology Prior Authorization with Cohere Health Integration

Navigating the complexities of prior authorization in oncology, especially with platforms like Cohere Health, requires specialized automation to ensure timely patient access to critical therapies.

Oncology prior authorization is among the most intricate and high-volume segments of healthcare, characterized by high-cost biologics, complex infusion regimens, and frequent treatment modifications. For revenue cycle directors and prior authorization coordinators, efficiently managing these approvals with payers utilizing AI-driven platforms like Cohere Health is paramount to preventing care delays and financial write-offs.

The Unique Challenges of Oncology Prior Authorization

Cancer care demands rapid treatment initiation, yet it involves a high cadence of prior authorization events across diagnosis, staging, treatment, and surveillance. From J-code chemotherapy and biologic infusions to advanced imaging and radiation oncology, each step often triggers a PA. The split between medical benefit and pharmacy benefit further complicates routing, requiring distinct pathways for IV infusions versus oral oncolytics.

Key Prior Authorization Triggers in Oncology

J-code chemotherapy and biologic infusions (e.g., immunotherapies, targeted therapies)
Advanced imaging for staging and surveillance (e.g., PET/CT, tumor-specific molecular imaging)
Radiation oncology procedures (e.g., IMRT, SBRT, proton-beam therapy)
Genetic and molecular testing (e.g., NGS panels for treatment selection)
Supportive care medications (e.g., G-CSF, ESAs, antiemetics, bone-targeting agents)

Navigating Cohere Health for Oncology Procedures and Therapies

Cohere Health operates as an AI-driven prior authorization platform for various payers, including Humana and Geisinger Health Plan. When a payer utilizes Cohere, oncology PA requests route through their system, requiring precise documentation and adherence to specific clinical criteria. Klivira's platform is engineered to integrate seamlessly, ensuring that the structured data and clinical rationale required by Cohere are accurately transmitted for medical benefit services, often via X12 278 or payer portals.

Meeting Documentation Requirements for Cohere Health Submissions

Successful oncology PA submissions to Cohere-enabled payers hinge on robust documentation aligned with NCCN Clinical Practice Guidelines and the NCCN Drugs & Biologics Compendium. This includes pathology reports, AJCC TNM staging, molecular marker results (e.g., ER/PR/HER2, EGFR/ALK/PD-L1), prior-line treatment response, and performance status (ECOG/Karnofsky). For off-label use, precise compendium citation is critical, as payer acceptance of categories can vary.

Klivira's Strategic Approach to Oncology Cohere Health Workflows

Klivira's platform provides specialized capabilities for oncology PA, designed to reduce administrative burden and accelerate approvals with platforms like Cohere Health. Our NCCN-compendium-aware policy logic surfaces required documentation at the point of order entry, while our regimen-level PA workflow bundles related components for streamlined submission. We manage the medical-vs-pharmacy benefit split and offer concurrent PA tracking for the dozens of events per patient, including integration for peer-to-peer scheduling to address clinical-necessity denials.

Frequently asked questions

How does Klivira handle the medical vs. pharmacy benefit split for oncology drugs when submitting to Cohere-enabled payers?

Klivira's platform intelligently routes oncology PA requests based on benefit type. For medical benefit drugs (IV infusions, biologics), submissions are directed through the payer's medical PA channel, often integrating with Cohere Health via X12 278 or payer portals. For pharmacy benefit oral oncolytics, the system routes through the payer's PBM and ePA partners, ensuring the correct workflow is followed for each drug.

What specific oncology documentation does Klivira help compile for Cohere Health submissions?

Klivira assists in compiling critical documentation for Cohere Health submissions, including pathology reports, tumor staging, molecular marker results, prior-line treatment history, and performance status (ECOG/Karnofsky scores). Our NCCN-compendium-aware logic highlights specific documentation requirements based on the proposed regimen and tumor type, ensuring all necessary clinical data is included to support medical necessity.

Can Klivira help reduce denials related to 'off-label use' or 'step therapy' when interacting with Cohere Health?

Yes, Klivira helps mitigate these common denial reasons. For off-label use, our system prompts for NCCN Compendium citations, ensuring submissions align with payer-accepted guidelines. For step therapy, Klivira can surface payer-specific requirements for prior failures or contraindications, helping to ensure the correct sequence of therapies is documented, thereby reducing denials from Cohere-enabled payers.

How does Klivira support the high volume of PA events per oncology patient, especially with platforms like Cohere Health?

Klivira provides concurrent PA tracking for the numerous authorization events an oncology patient may require throughout their treatment course. This includes initial regimen approvals, changes due to progression or toxicity, supportive care medications, and surveillance imaging. Our platform streamlines the submission process to Cohere Health and other payer portals, managing the multiple, ongoing PA cycles per patient.